Idiopathic pulmonary fibrosis
FJ Martinez, HR Collard, A Pardo, G Raghu… - Nature reviews Disease …, 2017 - nature.com
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …
Idiopathic pulmonary fibrosis
L Richeldi, HR Collard, MG Jones - The Lancet, 2017 - thelancet.com
Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …
An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline
G Raghu, B Rochwerg, Y Zhang… - American journal of …, 2015 - atsjournals.org
Background: This document updates the American Thoracic Society/European Respiratory
Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on …
Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on …
The emerging roles of interstitial macrophages in pulmonary fibrosis: a perspective from scRNA-seq analyses
Y Gu, T Lawrence, R Mohamed, Y Liang… - Frontiers in …, 2022 - frontiersin.org
Pulmonary fibrosis is an irreversible and progressive disease affecting the lungs, and the
etiology remains poorly understood. This disease can be lethal and currently has no specific …
etiology remains poorly understood. This disease can be lethal and currently has no specific …
A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis
G Raghu, M Mouded, DC Chambers… - American journal of …, 2022 - atsjournals.org
Rationale: Treatment options for idiopathic pulmonary fibrosis (IPF) are limited. Objectives:
To evaluate the efficacy and safety of BG00011, an anti-αvβ6 IgG1 monoclonal antibody, in …
To evaluate the efficacy and safety of BG00011, an anti-αvβ6 IgG1 monoclonal antibody, in …
Exosomal miR-17-5p from human embryonic stem cells prevents pulmonary fibrosis by targeting thrombospondin-2
Q Liu, Y Bi, S Song, K Zhu, X Qiao, H Wang… - Stem Cell Research & …, 2023 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible
lung disease characterized by pulmonary fibrosis and lung dysfunction, ultimately leading to …
lung disease characterized by pulmonary fibrosis and lung dysfunction, ultimately leading to …
European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
F Bonella, M Wijsenbeek… - European …, 2016 - Eur Respiratory Soc
Patient advocacy groups play an important role in supporting patients with chronic diseases
and promoting better care. The aim of this patient–physician initiative was to gather …
and promoting better care. The aim of this patient–physician initiative was to gather …
Idiopathic pulmonary fibrosis: epidemiology, natural history, phenotypes
J Sauleda, B Núñez, E Sala, JB Soriano - Medical Sciences, 2018 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial
pneumonias. It is characterized by a chronic, progressive, fibrotic interstitial lung disease of …
pneumonias. It is characterized by a chronic, progressive, fibrotic interstitial lung disease of …
Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial lung disease associated with
significant morbidity and mortality. Previously, IPF has been managed using …
significant morbidity and mortality. Previously, IPF has been managed using …
[PDF][PDF] Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape
MK Glassberg - Am J Manag Care, 2019 - ajmc.s3.amazonaws.com
Along with increasing age and male sex, potential risk factors for IPF include cigarette
smoking, environmental exposures, microbial pathogens, and genetic factors. 1 Anyone with …
smoking, environmental exposures, microbial pathogens, and genetic factors. 1 Anyone with …